Skip to main navigation Skip to search Skip to main content

Ovarian cancer and body size: Individual participant meta-analysis including 25,157 women with ovarian cancer from 47 epidemiological studies

  • V. Beral
  • , C. Hermon
  • , R. Peto
  • , G. Reeves
  • , L. Brinton
  • , P. Marchbanks
  • , E. Negri
  • , R. B. Ness
  • , P. H.M. Peeters
  • , M. Vessey
  • , E. E. Calle
  • , S. M. Gapstur
  • , A. V. Patel
  • , L. Dal Maso
  • , R. Talamini
  • , A. Chetrit
  • , G. Hirsh-Yechezkel
  • , F. Lubin
  • , S. Sadetzki
  • , N. Allen
  • D. Bull, K. Callaghan, B. Crossley, K. Gaitskell, A. Goodill, J. Green, T. Key, K. Moser, R. Collins, R. Doll, C. A. Gonzalez, N. Lee, H. W. Ory, H. B. Peterson, P. A. Wingo, N. Martin, T. Pardthaisong, S. Silpisornkosol, C. Theetranont, B. Boosiri, S. Chutivongse, P. Jimakorn, P. Virutamasen, C. Wongsrichanalai, A. Tjonneland, L. Titus-Ernstoff, T. Byers, T. Rohan, B. J. Mosgaard, D. Yeates, J. L. Freudenheim, J. Chang-Claude, R. Kaaks, K. E. Anderson, A. Folsom, M. A. Rossing, D. B. Thomas, N. S. Weiss, E. Riboli, F. Clavel-Chapelon, D. Cramer, K. Robien, S. S. Tworoger, D. Cramer, S. E. Hankinson, S. S. Tworoger, S. Franceschi, C. La Vecchia, C. Magnusson, T. Riman, E. Weiderpass, A. Wolk, L. J. Schouten, P. A. Van den Brandt, N. Chantarakul, S. Koetsawang, D. Rachawat, D. Palli, A. Black, A. Berrington de Gonzalez, D. M. Freedman, P. Hartge, A. W. Hsing, J. V. Lacey, R. N. Hoover, C. Schairer, S. Graff-Iversen, R. Selmer, C. J. Bain, A. C. Green, D. M. Purdie, V. Siskind, P. M. Webb, S. E. Mccann, P. Hannaford, C. Kay, C. W. Binns, A. H. Lee, M. Zhang, P. Nasca, P. F. Coogan, J. R. Palmer, L. Rosenberg, J. Kelsey, R. Paffenbarger, A. Whittemore, K. Katsouyanni, A. Trichopoulou, D. Trichopoulos, A. Tzonou, A. Dabancens, L. Martinez, R. Molina, O. Salas, M. T. Goodman, G. Lurie, M. E. Carney, L. R. Wilkens, L. Hartman, J. Manjer, H. Olsson, J. A. Grisso, M. Morgan, J. E. Wheeler, J. Casagrande, M. C. Pike, R. K. Ross, A. H. Wu, A. B. Miller, M. Kumle, E. Lund, L. Mcgowan, X. O. Shu, W. Zheng, T. M.M. Farley, S. Holck, O. Meirik, H. A. Risch
  • University of Oxford
  • University of Milan
  • University of Texas Health Science Center at Houston
  • Utrecht University
  • Department of Public Health
  • American Cancer Society
  • IRCCS Centro di Riferimento Oncologico - Aviano PN
  • The Gertner Institute
  • Institute Catala Oncologia
  • Centers for Disease Control and Prevention
  • Chiang Mai University
  • Chulalongkorn University
  • Danish Cancer Society
  • Dartmouth College
  • Colorado School of Public Health
  • Albert Einstein College of Medicine
  • University of Copenhagen
  • German Cancer Research Center
  • University of Minnesota Twin Cities
  • University of Washington
  • Imperial College London
  • University Paris-Sud
  • Harvard University
  • Brigham and Women’s Hospital
  • International Agency for Research on Cancer
  • Karolinska Institutet
  • Maastricht University
  • Mahidol University
  • Centro Per Lo Studio E La Prevenzione Oncologica
  • National Institutes of Health
  • Norwegian Institute of Public Health
  • Queensland Institute of Medical Research
  • Roswell Park Cancer Institute
  • Royal College of General Practitioners
  • Curtin University
  • University of Massachusetts Boston
  • Boston University
  • Stanford University
  • National and Kapodistrian University of Athens
  • Universidad de Chile
  • University of Hawai'i at Mānoa
  • Lund University
  • University of Pennsylvania
  • University of Southern California
  • University of Toronto
  • University of Tromsø – The Arctic University of Norway
  • George Washington University
  • Vanderbilt University
  • World Health Organization
  • Yale University

Research output: Contribution to journalArticlepeer-review

203 Scopus citations

Abstract

Background: Only about half the studies that have collected information on the relevance of women's height and body mass index to their risk of developing ovarian cancer have published their results, and findings are inconsistent. Here, we bring together the worldwide evidence, published and unpublished, and describe these relationships. Methods and Findings: Individual data on 25,157 women with ovarian cancer and 81,311 women without ovarian cancer from 47 epidemiological studies were collected, checked, and analysed centrally. Adjusted relative risks of ovarian cancer were calculated, by height and by body mass index. Ovarian cancer risk increased significantly with height and with body mass index, except in studies using hospital controls. For other study designs, the relative risk of ovarian cancer per 5 cm increase in height was 1.07 (95% confidence interval [CI], 1.05-1.09; p<0.001); this relationship did not vary significantly by women's age, year of birth, education, age at menarche, parity, menopausal status, smoking, alcohol consumption, having had a hysterectomy, having first degree relatives with ovarian or breast cancer, use of oral contraceptives, or use of menopausal hormone therapy. For body mass index, there was significant heterogeneity (p<0.001) in the findings between ever-users and never-users of menopausal hormone therapy, but not by the 11 other factors listed above. The relative risk for ovarian cancer per 5 kg/m2increase in body mass index was 1.10 (95% CI, 1.07-1.13; p<0.001) in never-users and 0.95 (95% CI, 0.92-0.99; p = 0.02) in ever-users of hormone therapy. Conclusions: Ovarian cancer is associated with height and, among never-users of hormone therapy, with body mass index. In high-income countries, both height and body mass index have been increasing in birth cohorts now developing the disease. If all other relevant factors had remained constant, then these increases in height and weight would be associated with a 3% increase in ovarian cancer incidence per decade.

Original languageEnglish
Article numbere1001200
JournalPLOS Medicine
Volume9
Issue number4
DOIs
StatePublished - Apr 1 2012

Fingerprint

Dive into the research topics of 'Ovarian cancer and body size: Individual participant meta-analysis including 25,157 women with ovarian cancer from 47 epidemiological studies'. Together they form a unique fingerprint.

Cite this